Cisapride in functional dyspepsia: a double-blind, placebo-controlled randomized trial in general practice patients.
This trial included patients from general practice with endoscopy-negative chronic dyspepsia and epigastric pain or discomfort. Eleven eligible patients with sufficiently severe dyspeptic symptoms after a 2-week placebo run-in period were entered into a 4-week, parallel group, double-blind randomized comparison of 10 mg cisapride three times daily and matched placebo, and were subsequently evaluable. Symptoms were comparable in the two treatment groups at the start of double-blind treatment. The cisapride group had a significantly greater reduction in the frequency of daytime epigastric pain/discomfort and the frequency and severity of nocturnal pain/discomfort after 2 weeks. After 2 weeks, all six cisapride recipients were free of nocturnal pain, compared with only one of five placebo recipients. After 4 weeks of double-blind therapy, improvements in the placebo group had reduced between-treatment differences, with five of six cisapride recipients and three of five placebo recipients being free of nocturnal pain. Cisapride was well tolerated.
University of Glasgow Dept. of General Practice, Woodside Health Centre, Scotland.
S F
SF
Wood
S C
SC
Penney
K M
KM
Cochran
D015746:Abdominal Pain / Q000188:drug therapy / Q000209:etiology; D000328:Adult; D000368:Aged; D002908:Chronic Disease; D020117:Cisapride; D004311:Double-Blind Method; D004415:Dyspepsia / Q000150:complications / Q000188:drug therapy*; D005194:Family Practice; D005260:Female; D005769:Gastrointestinal Motility / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010880:Piperidines / Q000627:therapeutic use*
D010880:Piperidines; D020117:Cisapride